Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients
Academic Article
Publication Date:
1999
abstract:
Several in vitro and animal studies have shown that IL-3 primes hematopoietic stem cells to become more sensitive to later acting growth factors. We wanted to compare the toxicity and the synergistic stimulatory effect of interleukin-3 (IL-3) followed by granulocyte colony-stimulating factor (G-CFS) or granulocyte-macrophage colony-stimulating factor (GM-CSF) on white blood cell (WBC) and platelet counts, after standard-dose chemotherapy (CT) in patients with solid tumors.
Iris type:
1.1 Articolo in rivista
Keywords:
Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukocyte Count; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Platelet Count; Prospective Studies; Thrombocytopenia; Treatment Outcome
List of contributors:
Palmeri, S; Leonardi, Valeria; Danova, M; Porta, C; Ferrari, S; Fincato, G; Citarrella, P
Published in: